MusclePharm Corporation MSLP OTC

MusclePharm Corporation (MSLP) generated $-8.04M in operating cash flow for fiscal year 2021. After capital expenditures of $2K, free cash flow was $-8.04M.

Free cash flow margin was -16.1% of revenue. Cash conversion ratio was 0.63x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (0/100, Fail) — weak cash flow raises concerns about debt servicing
• MOAT (7/100, Fail) — limited free cash flow weakens the competitive position
• INCOME (10/100) — Cash conversion ratio was 0.63x suggests some earnings are non-cash items

Overall SharesGrow Score: 11/100 with 0/7 criteria passed.